Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
暂无分享,去创建一个
M. Kurosumi | S. Kurozumi | H. Matsumoto | Kenichi Inoue | J. Horiguchi | T. Oyama | I. Takeyoshi | Y. Hayashi | K. Tozuka
[1] N. Ohuchi,et al. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers , 2016, Breast Cancer.
[2] Rory Stark,et al. Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.
[3] R. Gelber,et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] F. André,et al. Ki67—no evidence for its use in node-positive breast cancer , 2015, Nature Reviews Clinical Oncology.
[5] T. Miyazaki,et al. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility , 2015, Journal of Clinical Pathology.
[6] A. Luini,et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.
[7] John M S Bartlett,et al. An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.
[8] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] H. Iwase,et al. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens , 2013, Breast Cancer.
[10] C. Perou,et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Dowsett,et al. Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Harald Frick,et al. How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.
[13] Ben Tran,et al. Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.
[14] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[15] T. Osako,et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis , 2010, Breast cancer.
[16] S. Hayashi,et al. Estrogen signaling pathway and hormonal therapy , 2008, Breast cancer.
[17] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[18] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[19] Christopher J. Barnes,et al. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] Mitch Dowsett,et al. Aromatase inhibitors for breast cancer: lessons from the laboratory , 2003, Nature Reviews Cancer.
[21] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Molinolo,et al. Progesterone receptors - animal models and cell signalling in breast cancer: Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer , 2002, Breast Cancer Research.
[24] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[25] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[27] Takuji Iwase,et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy , 2013, Breast Cancer.
[28] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.